0P8 Stock Overview
Designs, develops, manufactures, and markets medical devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$225.80 |
| 52 Week High | US$254.00 |
| 52 Week Low | US$97.86 |
| Beta | 0.51 |
| 11 Month Change | 18.78% |
| 3 Month Change | 20.52% |
| 1 Year Change | 6.51% |
| 33 Year Change | -2.59% |
| 5 Year Change | 41.13% |
| Change since IPO | 532.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0P8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.1% | -0.4% | -0.4% |
| 1Y | 6.5% | -7.1% | 7.1% |
Return vs Industry: 0P8 exceeded the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: 0P8 matched the German Market which returned 7.1% over the past year.
Price Volatility
| 0P8 volatility | |
|---|---|
| 0P8 Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0P8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0P8's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 4,200 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands.
Penumbra, Inc. Fundamentals Summary
| 0P8 fundamental statistics | |
|---|---|
| Market cap | €8.70b |
| Earnings (TTM) | €32.75m |
| Revenue (TTM) | €1.10b |
265.7x
P/E Ratio7.9x
P/S RatioIs 0P8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0P8 income statement (TTM) | |
|---|---|
| Revenue | US$1.16b |
| Cost of Revenue | US$432.51m |
| Gross Profit | US$731.27m |
| Other Expenses | US$696.72m |
| Earnings | US$34.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.90 |
| Gross Margin | 62.84% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 0% |
How did 0P8 perform over the long term?
See historical performance and comparison